Skip to main content
      RT @uptoTate: Abs 0674 finds that HIT is rare among hospitalized APS and SLE patients with aPL and that anti-PF4 antibod

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Abs 0674 finds that HIT is rare among hospitalized APS and SLE patients with aPL and that anti-PF4 antibodies are often inappropriately tested in this population. #ACR22 @RheumNow https://t.co/hFZzpuEkDG https://t.co/hyUYVZLUM4
      RT @DrTrishHarkins: 🔥 VEXAS + the 🫁 🔥

      🔑 Points ~

      🫁 involvement common

      👉cough + dyspnea

      🌬PFT

      Patricia Harkins DrTrishHarkins

      3 years 10 months ago
      🔥 VEXAS + the 🫁 🔥 🔑 Points ~ 🫁 involvement common 👉cough + dyspnea 🌬PFTS often normal 🩻 CXR useful but HRCT superior 🩻ground glass opacity commonest finding 💊 good response GC 🔥ignite session🔥 #ACR22 Abst# 1569 @RheumNow
      RT @uptoTate: Abs 0345 finds association between cumulated HCQ and development of cardiac abnormalities. We need further

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Abs 0345 finds association between cumulated HCQ and development of cardiac abnormalities. We need further data to determine clinical association. #ACR22 @RheumNow https://t.co/WmixbFIlfd https://t.co/2Ejwkeu1Az
      RT @uptoTate: In the absence of other high risk factor for thrombosis, Thrombocytopenia (ITP) could be an independent an

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      In the absence of other high risk factor for thrombosis, Thrombocytopenia (ITP) could be an independent and long-lasting clinical phenotype for aPLs carriers. Abs 0672 #ACR22 @RheumNow https://t.co/LmlruGqkEJ https://t.co/MaIHS0QWN0
      RT @drdavidliew: Sometimes we guess how RA pts will be, before they come in.

      machine learning to predict RA dx activity

      David Liew drdavidliew

      3 years 10 months ago
      Sometimes we guess how RA pts will be, before they come in. machine learning to predict RA dx activity: RISE registry (n=39,155) inputs: prev CDAI, demo, smoking/obesity, SES v good performance Past performance does predict future outcomes, sometimes! ABST0905 #ACR22 @RheumNow https://t.co/Ir1YG1cqlD
      RheumNow’s expanded coverage of the #ACR22 meeting is sponsored in part by Bristol-Myers Squibb. All content chosen b

      Dr. John Cush RheumNow

      3 years 10 months ago
      RheumNow’s expanded coverage of the #ACR22 meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty
      RT @RichardPAConway: Park et al. Risk-benefit of PJP propylaxis in rituximab treated patients. NNH 86 . NNT - all RTX 14

      Richard Conway RichardPAConway

      3 years 10 months ago
      Park et al. Risk-benefit of PJP propylaxis in rituximab treated patients. NNH 86 . NNT - all RTX 146, RTX+high dose steroid 21. This mirrors my practice @RheumNow #ACR22 Abstr#0720 https://t.co/JPtPCqah9R https://t.co/bonRzWFbVw
      RT @doctorRBC: What neonatal factors could affect development into axSpA? Turns out antibiotic exposure (6.2x more likel

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      What neonatal factors could affect development into axSpA? Turns out antibiotic exposure (6.2x more likely). Mode of delivery, early diet (milk vs. formula), maternal smoking (!!) did not show association. @RheumNow #ACR22 Abs#0868 #ACRBest https://t.co/roCAj5YsCt
      RT @uptoTate: In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe in

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe infection compared to MTX, AZA, MMF. Abs 0349 #ACR22 @RheumNow https://t.co/0EBpCMPOqF https://t.co/vdxKVJSaZA
      RT @RichardPAConway: Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stab

      Richard Conway RichardPAConway

      3 years 10 months ago
      Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stabalised renal function (vs decline in PBO), less steroid increase (14% vs 36%), UPCR declined (vs increase in PBO) @RheumNow #ACR22 Abstr#1001 https://t.co/FRWcTAgCrn https://t.co/Amkg84OX2x
      RT @DrCassySims: 🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946

      SLE, birth control, & pregnancy pla

      Catherine Sims, MD DrCassySims

      3 years 10 months ago
      🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946 SLE, birth control, & pregnancy planning 🔥30% of women used no birth control despite only 17% voicing interest in pregnancy 🔥More 1/2 of women interested in pregnancy were not medically ready #ACR22 @RheumNow
      RT @RichardPAConway: Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc an

      Richard Conway RichardPAConway

      3 years 10 months ago
      Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc and UCTD most common. @RheumNow #ACR22 Abstr#0832 https://t.co/OU2hFn3ioK https://t.co/Ve0Jbexycm
      RT @RichardPAConway: Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucrava

      Richard Conway RichardPAConway

      3 years 10 months ago
      Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2
      ×